WHO ICTRP trial
Tofacitinib in early active axial spondyloarthritis: a prospective, randomized…
CTIS2023-505050-18-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2023-505050-18-00 |
|---|---|
| Public title | Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLANE |
| Scientific title | Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLANE - FASTLANE2022 |
| Primary sponsor | Charite Universitaetsmedizin Berlin KöR |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use - (Phase IV): yes |
| Countries | Bulgaria;Czechia;Germany;Poland |
| Conditions | Axial spondyloarthritis MedDRA version: 21.1Level: PTClassification code: 10071400Term: Axial spondyloarthritisSystem Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]-Diseases [C] - Musculoskeletal… |
| Interventions | Product Name: XELJANZ 5 mg film-coated tablets,Product Code: PRD6622190,Pharmaceutical Form: FILM-COATED TABLET,Other descriptive name: ,Strength: Tofacitinib 5mg,Product Name: Naproxen STADA® 500 mg Tabletten,Product Code… |
| Registration date | Jun 30, 2023 |
| Target size | 104 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: